Merck & Company Inc.

92.51+0.6200+0.67%Vol 8.43M1Y Perf 19.01%
Jun 29th, 2022 16:03 DELAYED
BID91.08 ASK93.00
Open92.31 Previous Close92.51
Pre-Market92.00 After-Market-
 -0.51 -0.55%  - -
Target Price
92.53 
Analyst Rating
Moderate Buy 2.00
Potential %
0.02 
Finscreener Ranking
★★★     49.98
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★+     53.97
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★+     55.38
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
★★+     42.97
Price Range Ratio 52W %
87.07 
Earnings Rating
Sell
Market Cap233.94B 
Earnings Date
28th Jul 2022
Alpha0.01 Standard Deviation0.06
Beta0.36 

Today's Price Range

91.8992.98

52W Range

70.8995.72

5 Year PE Ratio Range

16.3087.90

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.55%
1 Month
-0.61%
3 Months
12.27%
6 Months
19.92%
1 Year
19.01%
3 Years
10.33%
5 Years
44.34%
10 Years
147.36%

TickerPriceChg.Chg.%
MRK92.510.62000.67
AAPL139.231.79001.30
GOOG2 245.13-6.3000-0.28
MSFT260.263.78001.47
XOM88.12-3.3800-3.69
WFC39.71-0.4700-1.17
JNJ176.990.05000.03
FB196.640.99000.51
GE63.69-2.1900-3.32
JPM115.30-0.5200-0.45
Financial StrengthValueIndustryS&P 500US Markets
0.80
1.40
0.43
0.78
19.60
Leverage Ratio 2.70
ProfitabilityValueIndustryS&P 500US Markets
70.70
30.80
37.10
13.60
25.87
RevenueValueIndustryS&P 500US Markets
53.98B
21.35
5.02
5.38
DividendsValueIndustryS&P 500US Markets
2.92
2.76
7.86
7.89
Payout ratio104.00
Earnings HistoryEstimateReportedSurprise %
Q01 20221.812.1418.23
Q04 20211.461.8023.29
Q03 20211.541.7513.64
Q02 20211.331.31-1.50
Q01 20211.631.40-14.11
Q04 20201.361.32-2.94
Q03 20201.441.7420.83
Q02 20201.141.3720.18
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.68-6.15Negative
9/2022 QR1.87-1.06Negative
12/2022 FY7.321.39Positive
12/2023 FY7.190.70Positive
Next Report Date28th Jul 2022
Estimated EPS Next Report1.68
Estimates Count3
EPS Growth Next 5 Years %10.10
Volume Overview
Volume8.43M
Shares Outstanding2.53M
Shares Float2.53B
Trades Count101.22K
Dollar Volume779.26M
Avg. Volume12.16M
Avg. Weekly Volume12.61M
Avg. Monthly Volume12.13M
Avg. Quarterly Volume11.76M

Merck & Company Inc. (NYSE: MRK) stock closed at 92.51 per share at the end of the most recent trading day (a 0.67% change compared to the prior day closing price) with a volume of 8.43M shares and market capitalization of 233.94B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 74000 people. Merck & Company Inc. CEO is Robert M. Davis.

The one-year performance of Merck & Company Inc. stock is 19.01%, while year-to-date (YTD) performance is 20.71%. MRK stock has a five-year performance of 44.34%. Its 52-week range is between 70.89 and 95.72, which gives MRK stock a 52-week price range ratio of 87.07%

Merck & Company Inc. currently has a PE ratio of 16.70, a price-to-book (PB) ratio of 5.76, a price-to-sale (PS) ratio of 4.42, a price to cashflow ratio of 13.80, a PEG ratio of 2.32, a ROA of 14.74%, a ROC of 22.77% and a ROE of 42.76%. The company’s profit margin is 25.87%, its EBITDA margin is 37.10%, and its revenue ttm is $53.98 Billion , which makes it $21.35 revenue per share.

Of the last four earnings reports from Merck & Company Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.68 for the next earnings report. Merck & Company Inc.’s next earnings report date is 28th Jul 2022.

The consensus rating of Wall Street analysts for Merck & Company Inc. is Moderate Buy (2), with a target price of $92.53, which is +0.02% compared to the current price. The earnings rating for Merck & Company Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Merck & Company Inc. has a dividend yield of 2.92% with a dividend per share of $2.76 and a payout ratio of 104.00%.

Merck & Company Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.97, ATR14 : 2.09, CCI20 : 89.24, Chaikin Money Flow : 0.03, MACD : 0.74, Money Flow Index : 58.93, ROC : 6.11, RSI : 59.22, STOCH (14,3) : 74.66, STOCH RSI : 0.54, UO : 59.00, Williams %R : -25.34), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Merck & Company Inc. in the last 12-months were: Arpa Garay (Option Excercise at a value of $223 559), Caroline Litchfield (Option Excercise at a value of $144 559), Caroline Litchfield (Sold 18 335 shares of value $1 668 503 ), David Michael Williams (Option Excercise at a value of $180 590), Dean Y. Li (Option Excercise at a value of $161 854), Frank Clyburn (Option Excercise at a value of $207 622), Frank Clyburn (Sold 39 762 shares of value $3 493 879 ), Jannie Oosthuizen (Option Excercise at a value of $223 559), Julie L. Gerberding (Option Excercise at a value of $0), Julie L. Gerberding (Sold 192 540 shares of value $16 925 364 ), Kenneth C. Frazier (Option Excercise at a value of $0), Kenneth C. Frazier (Sold 663 881 shares of value $54 611 361 ), Lisa LeCointe-Cephas (Option Excercise at a value of $167 192), Michael A Klobuchar (Option Excercise at a value of $221 642), Richard R. DeLuca (Option Excercise at a value of $0), Richard R. DeLuca (Sold 165 187 shares of value $14 548 563 ), Rita A. Karachun (Option Excercise at a value of $244 023), Rita A. Karachun (Sold 25 000 shares of value $2 211 215 ), Sanat Chattopadhyay (Option Excercise at a value of $0), Sanat Chattopadhyay (Sold 24 619 shares of value $2 149 731 ), Steven C. Mizell (Option Excercise at a value of $415 156)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (50.00 %)
8 (50.00 %)
8 (47.06 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
8 (50.00 %)
8 (50.00 %)
9 (52.94 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.06

Merck & Company Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm's sales are generated in the United States.

CEO: Robert M. Davis

Telephone: +1 908 740-4000

Address: 2000 Galloping Hill Road, Kenilworth 07033, NJ, US

Number of employees: 74 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

61%39%

Bearish Bullish

66%34%

TipRanks News for MRK

Fri, 24 Jun 2022 16:24 GMT Merck Now What

- TipRanks. All rights reserved.

Fri, 29 Apr 2022 12:46 GMT Merck & Company (MRK) Receives a Buy from Wells Fargo

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 08:46 GMT Merck Reports Earnings Tomorrow What Can We Expect

- TipRanks. All rights reserved.

Tue, 26 Apr 2022 19:29 GMT Merck: A Dividend Growth Stock Worth Considering

- TipRanks. All rights reserved.

Wed, 13 Apr 2022 14:14 GMT Merck Stock: COVID-19 Drug Should Boost 2022 Numbers

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 18:20 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), SCYNEXIS (SCYX) and HTG Molecular Diagnostics (HTGM)

- TipRanks. All rights reserved.

Wed, 16 Mar 2022 01:57 GMT Merck & Company (MRK) Gets a Hold Rating from Berenberg Bank

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 16:44 GMT Merck: A Reliable Stock for Income Investors

- TipRanks. All rights reserved.

Mon, 07 Feb 2022 17:21 GMT Merck & Company (MRK) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Thu, 03 Feb 2022 13:15 GMT Merck & Company (MRK) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

Thu, 20 Jan 2022 14:25 GMT Merck & Company (MRK) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

Sun, 02 Jan 2022 12:27 GMT Is Merck & Co. a Value Stock

- TipRanks. All rights reserved.

News

Stocktwits